Merck’s Keytruda gets priority review from FDA for Merkel cell carcinoma indication

Image: Keytruda (pembrolizumab) Injection 100 mg /4mL . Photo: courtesy of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.